Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Wilms' Tumor
Researchers from University of Tubingen, Institute of Brain Research discuss findings in Wilms' tumor
February 18th, 2009
New investigation results, 'Diagnostic value of WT1 in neuroepithelial tumours,' are detailed in a study published in Neuropathology & Applied Neurobiology. "Currently, clinical trials using WT1 (Wilms tumor gene) peptide vaccines are conducted in haematopoietic malignancies and solid cancers. Single reports showed that the Wilms tumor gene product WT1 is also expressed in astrocytic neoplasms," investigators in Germany report. "Our aim was to investigate WT1 expression in a large cohort of various neuroepithelial tumours of different World Health Organization (WHO) grades and in normal central nervous system (CNS) tissue specimens to test its potential value as...
Source: Vaccine Weekly (2009-02-18)
|
